Rajwanshi A, Srinivas R, Upasana G. Malignant small round cell tumors. J Cytol. 2009;26(1):1–10.
Article
PubMed
PubMed Central
Google Scholar
Rong R, et al. Metastatic poorly differentiated monophasic synovial sarcoma to lung with unknown primary: a molecular genetic analysis. Int J Clin Exp Pathol. 2009;3(2):217–21.
PubMed
PubMed Central
Google Scholar
Thway K, Fisher C. Synovial sarcoma: defining features and diagnostic evolution. Ann Diagn Pathol. 2014;18(6):369–80.
Article
PubMed
Google Scholar
Kimura T, et al. Identification and analysis of CXCR4-positive synovial sarcoma-initiating cells. Oncogene. 2016;35(30):3932–43.
Article
CAS
PubMed
Google Scholar
Eilber FC, Dry SM. Diagnosis and management of synovial sarcoma. J Surg Oncol. 2008;97(4):314–20.
Article
PubMed
Google Scholar
Sultan I, et al. Comparing children and adults with synovial sarcoma in the Surveillance, Epidemiology, and End Results program, 1983 to 2005: an analysis of 1268 patients. Cancer. 2009;115(15):3537–47.
Article
PubMed
Google Scholar
Krieg AH, et al. Synovial sarcomas usually metastasize after >5 years: a multicenter retrospective analysis with minimum follow-up of 10 years for survivors. Ann Oncol. 2011;22(2):458–67.
Article
CAS
PubMed
Google Scholar
Deshmukh R, Mankin HJ, Singer S. Synovial sarcoma: the importance of size and location for survival. Clin Orthop Relat Res. 2004;419:155–61.
Article
Google Scholar
Vlenterie M, et al. Outcome of chemotherapy in advanced synovial sarcoma patients: Review of 15 clinical trials from the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group; setting a new landmark for studies in this entity. Eur J Cancer. 2016;58:62–72.
Article
PubMed
Google Scholar
Salah S, et al. Factors influencing survival in metastatic synovial sarcoma: importance of patterns of metastases and the first-line chemotherapy regimen. Med Oncol. 2013;30(3):639.
Article
PubMed
Google Scholar
Amankwah EK, Conley AP, Reed DR. Epidemiology and therapies for metastatic sarcoma. Clin Epidemiol. 2013;5:147–62.
PubMed
PubMed Central
Google Scholar
Spurrell EL, et al. Prognostic factors in advanced synovial sarcoma: an analysis of 104 patients treated at the Royal Marsden Hospital. Ann Oncol. 2005;16(3):437–44.
Article
CAS
PubMed
Google Scholar
Corey RM, Swett K, Ward WG. Epidemiology and survivorship of soft tissue sarcomas in adults: a national cancer database report. Cancer Med. 2014;3(5):1404–15.
Article
PubMed
PubMed Central
Google Scholar
Vlenterie M, Jones RL, van der Graaf WT. Synovial sarcoma diagnosis and management in the era of targeted therapies. Curr Opin Oncol. 2015;27(4):316–22.
Article
CAS
PubMed
Google Scholar
Kubo T, et al. Prognostic value of SS18-SSX fusion type in synovial sarcoma; systematic review and meta-analysis. Springerplus. 2015;4:375.
Article
PubMed
PubMed Central
Google Scholar
Kadoch C, Crabtree GR. Reversible disruption of mSWI/SNF (BAF) complexes by the SS18-SSX oncogenic fusion in synovial sarcoma. Cell. 2013;153(1):71–85.
Article
CAS
PubMed
PubMed Central
Google Scholar
Przybyl J, et al. Downstream and intermediate interactions of synovial sarcoma-associated fusion oncoproteins and their implication for targeted therapy. Sarcoma. 2012;2012:249219.
Article
PubMed
PubMed Central
Google Scholar
Garcia CB, Shaffer CM, Eid JE. Genome-wide recruitment to Polycomb-modified chromatin and activity regulation of the synovial sarcoma oncogene SYT-SSX2. BMC Genomics. 2012;13:189.
Article
CAS
PubMed
PubMed Central
Google Scholar
Su L, et al. Deconstruction of the SS18-SSX fusion oncoprotein complex: insights into disease etiology and therapeutics. Cancer Cell. 2012;21(3):333–47.
Article
CAS
PubMed
PubMed Central
Google Scholar
Rekhi B, et al. Immunohistochemical validation of TLE1, a novel marker, for synovial sarcomas. Indian J Med Res. 2012;136(5):766–75.
CAS
PubMed
PubMed Central
Google Scholar
Laporte AN et al. Identification of cytotoxic agents disrupting synovial sarcoma oncoprotein interactions by proximity ligation assay. Oncotarget, 2016;7(23):34384–94.
Panagopoulos I, et al. Clinical impact of molecular and cytogenetic findings in synovial sarcoma. Genes Chromosomes Cancer. 2001;31(4):362–72.
Article
CAS
PubMed
Google Scholar
Sun Y, et al. Prognostic implication of SYT-SSX fusion type and clinicopathological parameters for tumor-related death, recurrence, and metastasis in synovial sarcoma. Cancer Sci. 2009;100(6):1018–25.
Article
CAS
PubMed
Google Scholar
Ladanyi M, et al. Impact of SYT-SSX fusion type on the clinical behavior of synovial sarcoma: a multi-institutional retrospective study of 243 patients. Cancer Res. 2002;62(1):135–40.
CAS
PubMed
Google Scholar
Takenaka S, et al. Prognostic implication of SYT-SSX fusion type in synovial sarcoma: a multi-institutional retrospective analysis in Japan. Oncol Rep. 2008;19(2):467–76.
PubMed
Google Scholar
Fricke A, et al. Identification of a blood-borne miRNA signature of synovial sarcoma. Mol Cancer. 2015;14:151.
Article
PubMed
PubMed Central
Google Scholar
Masliah-Planchon J, Garinet S, Pasmant E. RAS-MAPK pathway epigenetic activation in cancer: miRNAs in action. Oncotarget. 2016;7(25):38892–907.
PubMed
Google Scholar
Hisaoka M, et al. Identification of altered MicroRNA expression patterns in synovial sarcoma. Genes Chromosomes Cancer. 2011;50(3):137–45.
Article
CAS
PubMed
Google Scholar
Fricke A, et al. Synovial Sarcoma Microvesicles Harbor the SYT-SSX Fusion Gene Transcript: Comparison of Different Methods of Detection and Implications in Biomarker Research. Stem Cells Int. 2016;2016:6146047.
Article
CAS
PubMed
PubMed Central
Google Scholar
Hashimoto N, et al. Detection of SYT-SSX fusion gene in peripheral blood from a patient with synovial sarcoma. Am J Surg Pathol. 2001;25(3):406–10.
Article
CAS
PubMed
Google Scholar
Chang L, et al. Circulating tumor cells in sarcomas: a brief review. Med Oncol. 2015;32(1):430.
Article
PubMed
Google Scholar
Chinen LT, et al. Isolation, detection, and immunomorphological characterization of circulating tumor cells (CTCs) from patients with different types of sarcoma using isolation by size of tumor cells: a window on sarcoma-cell invasion. Onco Targets Ther. 2014;7:1609–17.
Article
CAS
PubMed
PubMed Central
Google Scholar
Chibon F, et al. Validated prediction of clinical outcome in sarcomas and multiple types of cancer on the basis of a gene expression signature related to genome complexity. Nat Med. 2010;16(7):781–7.
Article
CAS
PubMed
Google Scholar
Lagarde P, et al. Chromosome instability accounts for reverse metastatic outcomes of pediatric and adult synovial sarcomas. J Clin Oncol. 2013;31(5):608–15.
Article
CAS
PubMed
Google Scholar
Gruneberg U, et al. KIF14 and citron kinase act together to promote efficient cytokinesis. J Cell Biol. 2006;172(3):363–72.
Article
CAS
PubMed
PubMed Central
Google Scholar
Ahmed SM, et al. KIF14 negatively regulates Rap1a-Radil signaling during breast cancer progression. J Cell Biol. 2012;199(6):951–67.
Article
CAS
PubMed
PubMed Central
Google Scholar
Vagnarelli P, et al. Repo-Man coordinates chromosomal reorganization with nuclear envelope reassembly during mitotic exit. Dev Cell. 2011;21(2):328–42.
Article
CAS
PubMed
Google Scholar
Hwa V, Oh Y, Rosenfeld RG. The insulin-like growth factor-binding protein (IGFBP) superfamily. Endocr Rev. 1999;20(6):761–87.
CAS
PubMed
Google Scholar
Chen D, et al. Insulin-like growth factor-binding protein-7 functions as a potential tumor suppressor in hepatocellular carcinoma. Clin Cancer Res. 2011;17(21):6693–701.
Article
CAS
PubMed
PubMed Central
Google Scholar
Burger AM, et al. Essential roles of IGFBP-3 and IGFBP-rP1 in breast cancer. Eur J Cancer. 2005;41(11):1515–27.
Article
CAS
PubMed
Google Scholar
Jiang W, et al. Insulin-like growth factor binding protein 7 mediates glioma cell growth and migration. Neoplasia. 2008;10(12):1335–42.
Article
CAS
PubMed
PubMed Central
Google Scholar
Shao L, et al. Detection of the differentially expressed gene IGF-binding protein-related protein-1 and analysis of its relationship to fasting glucose in Chinese colorectal cancer patients. Endocr Relat Cancer. 2004;11(1):141–8.
Article
CAS
PubMed
Google Scholar
Gambaro K, et al. Low levels of IGFBP7 expression in high-grade serous ovarian carcinoma is associated with patient outcome. BMC Cancer. 2015;15:135.
Article
PubMed
PubMed Central
Google Scholar
Nousbeck J, et al. Insulin-like growth factor-binding protein 7 regulates keratinocyte proliferation, differentiation and apoptosis. J Invest Dermatol. 2010;130(2):378–87.
Article
CAS
PubMed
Google Scholar
Wajapeyee N, et al. Oncogenic BRAF induces senescence and apoptosis through pathways mediated by the secreted protein IGFBP7. Cell. 2008;132(3):363–74.
Article
CAS
PubMed
PubMed Central
Google Scholar
Ahmed S, et al. Proteolytic processing of IGFBP-related protein-1 (TAF/angiomodulin/mac25) modulates its biological activity. Biochem Biophys Res Commun. 2003;310(2):612–8.
Article
CAS
PubMed
Google Scholar
Rao C, et al. High expression of IGFBP7 in fibroblasts induced by colorectal cancer cells is co-regulated by TGF-beta and Wnt signaling in a Smad2/3-Dvl2/3-dependent manner. PLoS One. 2014;9(1):e85340.
Article
PubMed
PubMed Central
Google Scholar
Padua D, Massague J. Roles of TGFbeta in metastasis. Cell Res. 2009;19(1):89–102.
Article
CAS
PubMed
Google Scholar
Massague J. TGFbeta in Cancer. Cell. 2008;134(2):215–30.
Article
CAS
PubMed
PubMed Central
Google Scholar
Pen A, et al. Glioblastoma-secreted factors induce IGFBP7 and angiogenesis by modulating Smad-2-dependent TGF-beta signaling. Oncogene. 2008;27(54):6834–44.
Article
CAS
PubMed
Google Scholar
Benassi MS, et al. Tissue and serum IGFBP7 protein as biomarker in high-grade soft tissue sarcoma. Am J Cancer Res. 2015;5(11):3446–54.
PubMed
PubMed Central
Google Scholar
Palmerini E, et al. Prognostic and predictive role of CXCR4, IGF-1R and Ezrin expression in localized synovial sarcoma: is chemotaxis important to tumor response? Orphanet J Rare Dis. 2015;10:6.
Article
PubMed
PubMed Central
Google Scholar
Wan X, Helman LJ. The biology behind mTOR inhibition in sarcoma. Oncologist. 2007;12(8):1007–18.
Article
PubMed
Google Scholar
Roomi MW, et al. Modulation of u-PA, MMPs and their inhibitors by a novel nutrient mixture in adult human sarcoma cell lines. Int J Oncol. 2013;43(1):39–49.
CAS
PubMed
PubMed Central
Google Scholar
Willis BC, Borok Z. TGF-beta-induced EMT: mechanisms and implications for fibrotic lung disease. Am J Physiol Lung Cell Mol Physiol. 2007;293(3):L525–34.
Article
CAS
PubMed
Google Scholar
Benassi MS, et al. Metalloproteinase expression and prognosis in soft tissue sarcomas. Ann Oncol. 2001;12(1):75–80.
Article
CAS
PubMed
Google Scholar
Hidalgo M, Eckhardt SG. Development of matrix metalloproteinase inhibitors in cancer therapy. J Natl Cancer Inst. 2001;93(3):178–93.
Article
CAS
PubMed
Google Scholar
Ferrari C, et al. Role of MMP-9 and its tissue inhibitor TIMP-1 in human osteosarcoma: findings in 42 patients followed for 1–16 years. Acta Orthop Scand. 2004;75(4):487–91.
Article
PubMed
Google Scholar
Benassi MS, et al. Tissue and serum loss of metalloproteinase inhibitors in high grade soft tissue sarcomas. Histol Histopathol. 2003;18(4):1035–40.
CAS
PubMed
Google Scholar
Moran A, et al. Clinical relevance of MMP-9, MMP-2, TIMP-1 and TIMP-2 in colorectal cancer. Oncol Rep. 2005;13(1):115–20.
CAS
PubMed
Google Scholar
Way G, et al. Purification and identification of secernin, a novel cytosolic protein that regulates exocytosis in mast cells. Mol Biol Cell. 2002;13(9):3344–54.
Article
CAS
PubMed
PubMed Central
Google Scholar
Hendrix A, et al. The tumor ecosystem regulates the roads for invasion and metastasis. Clin Res Hepatol Gastroenterol. 2011;35(11):714–9.
Article
CAS
PubMed
Google Scholar
Lin S, et al. Secernin-1 contributes to colon cancer progression through enhancing matrix metalloproteinase-2/9 exocytosis. Dis Markers. 2015;2015:230703.
Article
PubMed
PubMed Central
Google Scholar
Miyoshi N, et al. SCRN1 is a novel marker for prognosis in colorectal cancer. J Surg Oncol. 2010;101(2):156–9.
CAS
PubMed
Google Scholar
Suehara Y, et al. Secernin-1 as a novel prognostic biomarker candidate of synovial sarcoma revealed by proteomics. J Proteomics. 2011;74(6):829–42.
Article
CAS
PubMed
Google Scholar
Wang W, et al. Polycomb Group (PcG) Proteins and Human Cancers: Multifaceted Functions and Therapeutic Implications. Med Res Rev. 2015;35(6):1220–67.
Article
CAS
PubMed
PubMed Central
Google Scholar
Volkel P, et al. Diverse involvement of EZH2 in cancer epigenetics. Am J Transl Res. 2015;7(2):175–93.
CAS
PubMed
PubMed Central
Google Scholar
Changchien YC, et al. Poorly differentiated synovial sarcoma is associated with high expression of enhancer of zeste homologue 2 (EZH2). J Transl Med. 2012;10:216.
Article
CAS
PubMed
PubMed Central
Google Scholar
Kawano S, et al. Preclinical Evidence of Anti-Tumor Activity Induced by EZH2 Inhibition in Human Models of Synovial Sarcoma. PLoS One. 2016;11(7):e0158888.
Article
PubMed
PubMed Central
Google Scholar
Ramaglia M, et al. High EZH2 expression is correlated to metastatic disease in pediatric soft tissue sarcomas. Cancer Cell Int. 2016;16:59.
Article
PubMed
PubMed Central
Google Scholar
Yamaguchi H, Hung MC. Regulation and Role of EZH2 in Cancer. Cancer Res Treat. 2014;46(3):209–22.
Article
CAS
PubMed
PubMed Central
Google Scholar
Fujii S, et al. Enhancer of zeste homologue 2 (EZH2) down-regulates RUNX3 by increasing histone H3 methylation. J Biol Chem. 2008;283(25):17324–32.
Article
CAS
PubMed
PubMed Central
Google Scholar
Moore HM, et al. EZH2 inhibition decreases p38 signaling and suppresses breast cancer motility and metastasis. Breast Cancer Res Treat. 2013;138(3):741–52.
Article
CAS
PubMed
PubMed Central
Google Scholar
Schultz-Thater E, et al. NY-ESO-1 tumour associated antigen is a cytoplasmic protein detectable by specific monoclonal antibodies in cell lines and clinical specimens. Br J Cancer. 2000;83(2):204–8.
Article
CAS
PubMed
PubMed Central
Google Scholar
Park TS, et al. Expression of MAGE-A and NY-ESO-1 in Primary and Metastatic Cancers. J Immunother. 2016;39(1):1–7.
Article
CAS
PubMed
Google Scholar
Li M, et al. Effective inhibition of melanoma tumorigenesis and growth via a new complex vaccine based on NY-ESO-1-alum-polysaccharide-HH2. Mol Cancer. 2014;13:179.
Article
PubMed
PubMed Central
Google Scholar
Giesen E, et al. NY-ESO-1 as a potential immunotherapeutic target in renal cell carcinoma. Oncotarget. 2014;5(14):5209–17.
Article
PubMed
PubMed Central
Google Scholar
Aung PP, et al. Expression of New York esophageal squamous cell carcinoma-1 in primary and metastatic melanoma. Hum Pathol. 2014;45(2):259–67.
Article
PubMed
Google Scholar
Lai JP, et al. NY-ESO-1 expression in sarcomas: A diagnostic marker and immunotherapy target. Oncoimmunol. 2012;1(8):1409–10.
Article
Google Scholar
Robbins PF, et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol. 2011;29(7):917–24.
Article
PubMed
PubMed Central
Google Scholar
Xu C, et al. CXCR4 in breast cancer: oncogenic role and therapeutic targeting. Drug Des Devel Ther. 2015;9:4953–64.
PubMed
PubMed Central
Google Scholar
Dewan MZ, et al. Stromal cell-derived factor-1 and CXCR4 receptor interaction in tumor growth and metastasis of breast cancer. Biomed Pharmacother. 2006;60(6):273–6.
Article
CAS
PubMed
Google Scholar
Gangadhar T, Nandi S, Salgia R. The role of chemokine receptor CXCR4 in lung cancer. Cancer Biol Ther. 2010;9(6):409–16.
Article
CAS
PubMed
Google Scholar
Lv S, et al. The association of CXCR4 expression with prognosis and clinicopathological indicators in colorectal carcinoma patients: a meta-analysis. Histopathology. 2014;64(5):701–12.
Article
PubMed
Google Scholar
Scala S, et al. Expression of CXCR4 predicts poor prognosis in patients with malignant melanoma. Clin Cancer Res. 2005;11(5):1835–41.
Article
CAS
PubMed
Google Scholar
Oda Y, et al. Chemokine receptor CXCR4 expression is correlated with VEGF expression and poor survival in soft-tissue sarcoma. Int J Cancer. 2009;124(8):1852–9.
Article
CAS
PubMed
Google Scholar
Yuecheng Y, Xiaoyan X. Stromal-cell derived factor-1 regulates epithelial ovarian cancer cell invasion by activating matrix metalloproteinase-9 and matrix metalloproteinase-2. Eur J Cancer Prev. 2007;16(5):430–5.
Article
PubMed
Google Scholar
Uchida D, et al. Possible role of stromal-cell-derived factor-1/CXCR4 signaling on lymph node metastasis of oral squamous cell carcinoma. Exp Cell Res. 2003;290(2):289–302.
Article
CAS
PubMed
Google Scholar
Guo F, et al. CXCL12/CXCR4: a symbiotic bridge linking cancer cells and their stromal neighbors in oncogenic communication networks. Oncogene. 2016;35(7):816–26.
Article
CAS
PubMed
Google Scholar
Kim RH, Li BD, Chu QD. The role of chemokine receptor CXCR4 in the biologic behavior of human soft tissue sarcoma. Sarcoma. 2011;2011:593708.
PubMed
Google Scholar
Murphy PM. Chemokines and the molecular basis of cancer metastasis. N Engl J Med. 2001;345(11):833–5.
Article
CAS
PubMed
Google Scholar
Muller A, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature. 2001;410(6824):50–6.
Article
CAS
PubMed
Google Scholar
Debnath B, et al. Small molecule inhibitors of CXCR4. Theranostics. 2013;3(1):47–75.
Article
CAS
PubMed
PubMed Central
Google Scholar
Kim SY, et al. Inhibition of the CXCR4/CXCL12 chemokine pathway reduces the development of murine pulmonary metastases. Clin Exp Metastasis. 2008;25(3):201–11.
Article
CAS
PubMed
Google Scholar